Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.24 USD | -5.01% | -4.78% | -28.14% |
Apr. 23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
Apr. 22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
Evolution of the average Target Price on Legend Biotech Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Legend Biotech Corporation
Scotiabank | |
Cantor Fitzgerald | |
UBS | |
Raymond James | |
RBC Capital Markets | |
HC Wainwright | |
Barclays | |
Morgan Stanley | |
BTIG | |
William Blair & Co. | |
Daiwa Securities | |
BMO Capital | |
JPMorgan Chase | |
Piper Sandler | |
Cowen | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- LEGN Stock
- Consensus Legend Biotech Corporation